Guardant Health Inc GH
News
Guardant Health to Share Data at ESMO 2024 Further Demonstrating Strong Performance of Its Precision Oncology Technology in Multiple Advanced Tumor Types
Guardant Health and Policlinico Gemelli Announce Partnership to Establish A Dedicated In-House Liquid Biopsy Testing Service in Italy
Guardant Health to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference
Guardant Health to Ring the Nasdaq Opening Bell on August 28 to Celebrate the Launch of Shield™ Blood Test for Colorectal Cancer Screening
Guardant Health to Participate in Upcoming Investor Conferences
Guardant Health Reports Second Quarter 2024 Financial Results and Increases 2024 Revenue Guidance
Guardant Health COSMOS Study Published in Clinical Cancer Research Validates Utility of Guardant Reveal™ Liquid Biopsy Test for Predicting Recurrence in Colorectal Cancer
Guardant Health’s FDA-approved Shield™ Blood Test Now Commercially Available in U.S. as a Primary Screening Option for Colorectal Cancer
Guardant Health Outcomes Model Confirms the Public Health Importance of Enhanced Colorectal Cancer Screening Outcomes with High Adherence Strategies
Guardant Health's stock up after FDA approves its blood test for colon-cancer screening
Guardant Health’s Shield™ Blood Test Approved by FDA as a Primary Screening Option, Clearing Path for Medicare Reimbursement and a New Era of Colorectal Cancer Screening
Guardant Health to Report Second Quarter 2024 Financial Results on August 7, 2024
Guardant Health Introduces Major Smart Liquid Biopsy Upgrade to Market-Leading Guardant360® Test, Further Extending Its Best-in-Class Performance
Dr. Manuel Hidalgo Medina Joins Guardant Health Board of Directors
Guardant Health Gets FDA Panel Recommendation for Cancer-Screening Blood Test
Guardant Health shares slide as colon cancer test is set for FDA advisory committee review